Drug intelligence / Profile preview

APSTZD

Development stage: Phase 2
Lead developer: Apsen Farmacêutica
Modality: Small Molecules
Administration: Oral

Overview

**APSTZD** is an investigational Apsen Farmaceutica drug candidate being evaluated for the treatment of chronic insomnia disorder. It is being studied in the randomized, double-blind, double-dummy Phase II TINA trial, which compares four APSTZD treatment arms with zolpidem extended-release and placebo over six weeks. The publicly available trial record does not disclose APSTZD's chemical identity, molecular target, or pharmacologic mechanism; it should therefore be treated as a distinct sponsor-coded investigational asset rather than mapped to zolpidem or another established hypnotic.

Other names: trazodone

Targets

HTR2A (Serotonin receptor 5-HT2A)ADRA1A (α1A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on APSTZD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APSTZD.

Explore the full profile